REBECA trial: a new piece of the evidence for bevacizumab in platinum-resistant recurrent ovarian cancer

Daniele Lavacchi, Sara Fancelli, Marta Rita Gatta Michelet, Martina Catalano, Giandomenico Roviello

Abstract

Lee et al. (1) evaluated the efficacy and safety of bevacizumab in combination with single-agent chemotherapy for platinum-resistant ovarian cancer in a large retrospective analysis involving Korean women with platinum-resistant recurrent ovarian cancer from 27 different institutions.

Article Options

Download Citation